Deferasirox
Deferasorox, Exjade, Jadenu
Iron Chelator
NADAC/unit
$0.8750
No Shortage
Tier 1: 93.0%
PA Req: 455.0%
17 Manufacturers
75 ANDAs
an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox tablets are indicated for the treatment of ....
vs. brand Deferasorox: Generic saves up to 91% per unit
Market Intelligence
2023-11-15 Class II Recall: Glenmark Pharmaceuticals Inc., USA
Generic Manufacturers
ACTAVIS ELIZABETH LLCALEMBIC PHARMACEUTICALS LTDALKEM LABORATORIES LTDANNORA PHARMA PRIVATE LTDAUCTA PHARMACEUTICALS INCAUROBINDO PHARMA LTDBIONPHARMA INCCHARTWELL RX SCIENCES LLCCIPLA LTDGLENMARK SPECIALTY SAJUBILANT GENERICS LTDMSN LABORATORIES PRIVATE LTDNOVARTIS PHARMACEUTICALS CORPPHARMOBEDIENT CONSULTING LLCPIRAMAL HEALTHCARE UK LTDSUN PHARMACEUTICAL INDUSTRIES LTDTEVA PHARMACEUTICALS USA INCZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.